Box 4

Scope and Contents:

Contains correspondence on Xerosin and Neomycin patents.

Scope and Contents:

Contains a paper on the preparation of a culture from a strain of actinomyces, and correspondence with drug firms from 1951.

Scope and Contents:

Contains three units of correspondence on tests using Fradicin, especially against candida albicans: 1) State of New York Department of Health and the Commercial Solvents Corporation; 2) University of Pennsylvania School of Dentistry; and 3) Veterans Administration Hospital, San Fernando, CA.

Scope and Contents: Contains letter dated October 18, 1960 to Director of Patents, UCLAF, Paris, regarding a license agreement to manufacture Neomycin, which was isolated at Rutgers University in 1948, the first license agreement issued 1952, and the patent granted in France May 7, 1952 (photocopy of patent application in French). There are three research papers/reports by Rutgers' scientists in the file detailing the nature of the Neomycin complex. UCLAF had discovered at the same...

Scope and Contents:

SAW holds the patent for the process of production with partial assignment from Merck to Pfizer. The folder contains the correspondence, memoranda, patents, and patent assignments.

Scope and Contents:

Correspondence, memoranda, patents and license agreements between Rutgers, Mearl, (a Canadian company) and Merck.

Scope and Contents: There are restricted minutes of meetings between 1942 and 1946 of the National Research Council Committee on Medical Research and the Committee on Chemotherapeutics and Other Agents; FDA report on Tentative Minimum Specifications for Streptomycin-Standards of Identity, Strength, Quality and Purity, 1946; paper on tuberculosis delivered by Dr. J. Wilson, 1954; reprint from Science magazine of March 29, 1957 of an article by SAW on...

Scope and Contents:

Correspondence with companies worldwide regarding patents granted for "Polyenic Compounds and Procedures related Thereto," No. 77,847 dated March 29, 1961, as well as disclosure agreements and license agreements. The letters all enclose copies of three scientific papers being submitted for publication by the staff of the Institute.

Scope and Contents: Contains correspondence with the law firm of Cooper, Dunham, Dearborn, and Henninger (the last of three name changes during the indicated time span) regarding the patent application filed on September 9, 1952 for Candicidin as a fungi fighter, and subsequent supplements filed April 7, 1955 and July 22, 1955 because of a problem with the precise identification of the antibiotic, and a conflict with an antibiotic named Ascosin, produced by Commercial Solvents Corp....

Scope and Contents:

The file contains correspondence on clinical trials, toxicity, and license agreements; reports on chemical analysis of Candicidin and comparison with Ascosin; and file memoranda.